Latest & greatest articles for propranolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on propranolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on propranolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for propranolol

21. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding.

Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. 10099140 1999 04 01 1999 04 01 2013 11 21 0028-4793 340 13 1999 Apr 01 The New England journal of medicine N. Engl. J. Med. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. 988-93 We compared propranolol therapy and endoscopic ligation for the primary prevention of bleeding from esophageal varices. This prospective, controlled trial included (...) consecutive eligible patients who had large varices (>5 mm in diameter) that were at high risk for bleeding. The patients were assigned to either propranolol therapy, at a dose sufficient to decrease the base-line heart rate by 25 percent, or variceal ligation, to be performed weekly until the varices were obliterated or so reduced in size that it was not possible to continue treatment. Of the 89 patients, 82 of whom had cirrhosis of the liver, 44 received propranolol and 45 underwent variceal ligation

NEJM1999

22. Propranolol and sclerotherapy in the prevention of gastrointestinal Rebleeding in patients with cirrhosis: a meta-analysis

Propranolol and sclerotherapy in the prevention of gastrointestinal Rebleeding in patients with cirrhosis: a meta-analysis Propranolol and sclerotherapy in the prevention of gastrointestinal Rebleeding in patients with cirrhosis: a meta-analysis Propranolol and sclerotherapy in the prevention of gastrointestinal Rebleeding in patients with cirrhosis: a meta-analysis Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T Authors' objectives To assess the efficacy of the beta-blocker propranolol (...) (RCTs). In addition, the studies had to be published as an abstract or article; include patients with cirrhosis and oesophageal varices, patients enrolled after initial rebleeding from oesophageal varices, and patients in whom bleeding was not treated with sclerotherapy; a comparison of propranolol with endoscopic sclerotherapy; have a mean follow-up of more than 11 months; and have at least one of the previously mentioned end points. Specific interventions included in the review Propranolol

DARE.1997

23. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding.

Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. 9107241 1997 04 30 1997 04 30 2015 06 16 0140-6736 349 9058 1997 Apr 12 Lancet (London, England) Lancet Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. 1043-9 The transjugular-intrahepatic-portosystemic shunt is a new interventional treatment for portal hypertension (...) at the time of shunt placement. Endoscopic treatment consisted of sclerotherapy and/or banding ligation and was combined with propranolol medication. Technical success was achieved in all patients assigned to the shunt group. During follow-up, the cumulative 1-year variceal rebleeding rates in the shunted and endoscopically treated patients were 15% and 41% and the 2-year rates were 21% and 52% (p = 0.001), respectively. In nine (12%) patients from the endoscopic group treatment failed and the patients

Lancet1997

24. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis.

Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. 1675316 1991 07 17 1991 07 17 2015 06 16 0140-6736 337 8755 1991 Jun 15 Lancet (London, England) Lancet Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. 1431-4 The two main causes of gastrointestinal bleeding in cirrhosis are oesophageal varices and portal hypertensive gastropathy (PHG). Rebleeding from varices can be prevented (...) by beta-blockers, but it is not clear whether these drugs effectively reduce rebleeding from PHG. 54 cirrhotic patients with acute or chronic bleeding from severe PHG took part in a randomised, controlled trial to investigate the efficacy of propranolol in prevention of rebleeding from PHG. 26 patients were randomised to receive propranolol daily at a dose that reduced the resting heart rate by 25% or to 55 bpm (20-160 mg twice daily), throughout mean follow-up of 21 (SD 11) months. 28 untreated

Lancet1991

25. Long term propranolol treatment and changes in body weight after myocardial infarction.

Long term propranolol treatment and changes in body weight after myocardial infarction. 2186832 1990 06 18 1990 06 18 2013 11 21 0959-8138 300 6729 1990 Apr 07 BMJ (Clinical research ed.) BMJ Long term propranolol treatment and changes in body weight after myocardial infarction. 902-3 To determine the effect of long term propranolol treatment on body weight. Retrospective analysis of data from a placebo controlled randomised double blind clinical trial (the beta blocker heart attack trial (...) ). 3837 Men and women randomised 5-21 days after an acute myocardial infarction to treatment with placebo or propranolol for up to 40 months. Patients were followed up at annual visits. Changes in body weight. At the first annual visit patients treated with propranolol had gained more weight than those given placebo (mean weight gain 2.3 kg v 1.2 kg respectively, mean difference 1.2 kg (95% confidence interval 0.9 to 1.5]. These group differences remained at the second and third annual visits

BMJ1990 Full Text: Link to full Text with Trip Pro

26. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis.

Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. 2502256 1989 08 29 1989 08 29 2013 11 21 0959-8138 298 6684 1989 May 20 BMJ (Clinical research ed.) BMJ Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. 1363-5 Fifty patients with non-cirrhotic portal fibrosis who were admitted to hospital because of upper gastrointestinal bleeding were randomly assigned (...) to treatment with either oral propranolol given in doses that reduced the resting pulse rate by 25% (25 patients) or with a placebo (25 patients). One year after the start of the study 20 patients in the propranolol group and five patients in the placebo group were free from recurrent gastrointestinal bleeding (p less than 0.0001). Giving continuous oral propranolol treatment is therefore effective in preventing recurrent upper gastrointestinal bleeding in patients with non-cirrhotic portal fibrosis. Kiire

BMJ1989 Full Text: Link to full Text with Trip Pro

27. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices.

Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. 3306385 1987 10 20 1987 10 20 2013 11 21 0028-4793 317 14 1987 Oct 01 The New England journal of medicine N. Engl. J. Med. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. 856-61 We conducted a prospective, randomized, multicenter, single-blind trial (...) of propranolol as compared with placebo in the prevention of first upper gastrointestinal tract bleeding in patients with cirrhosis of the liver. A total of 230 patients (90 percent with alcoholism and 46 percent with a Child-Pugh grade C classification) with large esophageal varices without previous bleeding were randomly assigned to receive either propranolol (n = 118) or placebo (n = 112), after they had been divided into two groups according to the severity of their liver disease. The end points

NEJM1987

28. A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response.

A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. 3531560 1986 11 07 1986 11 07 2016 10 17 0098-7484 256 16 1986 Oct 24-31 JAMA JAMA A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. 2214-21 We compared verapamil and propranolol hydrochloride for monotherapy of hypertension. Verapamil lowered blood pressure (BP) more effectively than propranolol in black (...) and white patients. Verapamil was equally effective in blacks and whites, whereas propranolol was more effective in whites. Heart rate was reduced by 6.0 beats per minute by verapamil, and by 13.6 beats per minute by propranolol. In blacks, verapamil lowered systolic BP 16.9 vs 8.1 mm Hg for propranolol; verapamil reduced diastolic BP 12.8 vs 8.6 mm Hg for propranolol. In whites, verapamil lowered systolic BP 19.0 vs 12.7 mm Hg for propranolol; verapamil reduced diastolic BP 16.7 vs 12.3 mm Hg

JAMA1986

29. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.

Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. 2857210 1985 03 06 1985 03 06 2015 06 16 0140-6736 1 8421 1985 Jan 19 Lancet (London, England) Lancet Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. 123-6 14 hypertensive men with type II diabetes sequentially received, in random order, hydrochlorothiazide 50 mg twice (...) a day, propranolol 80 mg twice a day, and both drugs in combination. The 3-week treatment periods were separated by a 1-week washout period. Hydrochlorothiazide significantly increased fasting glucose by 31% (p less than 0.05) and glycosylated haemoglobin (HbA1c) by 6.0% (p less than 0.10). A similar treatment period of propranolol 80 mg twice a day caused no significant increases. However, when both drugs were taken in combination, fasting glucose rose by 56% and HbA1c by 14.7% (p less than 0.01

Lancet1985

30. Therapeutic effect of propranolol on paradoxical hypertension after repair of coarctation of the aorta.

Therapeutic effect of propranolol on paradoxical hypertension after repair of coarctation of the aorta. 3887159 1985 05 30 1985 05 30 2013 11 21 0028-4793 312 19 1985 May 09 The New England journal of medicine N. Engl. J. Med. Therapeutic effect of propranolol on paradoxical hypertension after repair of coarctation of the aorta. 1224-8 Patients undergoing repair of coarctation of the aorta often have self-limited but severe hypertension in the first week after surgery (paradoxical hypertension (...) ). We conducted a controlled trial of treatment with propranolol before repair of coarctation of the aorta in 14 children to determine whether the drug would prevent paradoxical hypertension. Seven patients were randomly assigned to receive propranolol for two weeks before surgery and throughout the first postoperative week, and seven patients were assigned to receive standard postoperative care. Both groups had a similar significant (P less than 0.05) increase in the plasma norepinephrine level

NEJM1985

31. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine.

Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. 6366561 1984 04 26 1984 04 26 2013 11 21 0028-4793 310 15 1984 Apr 12 The New England journal of medicine N. Engl. J. Med. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. 951-4 To determine whether cigarette smoking affects the results of drug treatment for angina, we studied 10 cigarette smokers with angina who were given placebo, nifedipine (60 mg per day (...) ), propranolol (240 mg per day), and atenolol (100 mg per day), each for one week. The four-week double-blind study was repeated with the same randomly determined order of drug sequences, after all 10 subjects had stopped smoking. Before and after the subjects stopped smoking, all three drugs significantly reduced the frequency of angina, as measured with angina diaries, and improved the results of maximal exercise testing and 48-hour ambulatory monitoring of ST segments (P less than 0.01). However, during

NEJM1984

32. Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial.

Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. 6377070 1984 08 13 1984 08 13 2013 11 21 0028-4793 311 4 1984 Jul 26 The New England journal of medicine N. Engl. J. Med. Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. 218-25 A multicenter randomized single-blind study was performed to evaluate the effects of propranolol administered during the evolution of myocardial infarction. Five centers enrolled a total (...) of 269 patients, with 134 receiving propranolol and 135 placebo. Propranolol or placebo was given intravenously upon randomization (0.1 mg per kilogram of body weight) and then orally for nine days to keep the heart rate between 45 and 60 beats per minute. Less than 2 per cent of patients were treated within 4 hours after the onset of symptoms, but 50 per cent received therapy within 8 hours of onset of chest pain, and the remainder between 8 and 18 hours. The heart rates in the propranolol-treated

NEJM1984

33. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol.

Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. 6148617 1984 11 16 1984 11 16 2015 06 16 0140-6736 2 8408 1984 Oct 20 Lancet (London, England) Lancet Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. 883-6 A trial of intravenous followed by oral propranolol, started within 4 h of onset of suspected myocardial infarction and continued over 27 h, was carried out in 735 patients; 364 received (...) propranolol, 371 were controls. Ventricular fibrillation during the first 48 h after entry to the trial occurred in 2 treated patients and in 14 controls (p = 0.006). Rates of hospital mortality, complications other than ventricular fibrillation, and progression from threatened to completed infarction did not differ between treated and control patients. Ventricular fibrillation was not apparently prevented by prior beta-blocker treatment, which was not a reason for exclusion from the trial

Lancet1984

34. Influence of propranolol on weight and salt and water homoeostasis in chronic liver disease.

Influence of propranolol on weight and salt and water homoeostasis in chronic liver disease. 6150141 1984 12 27 1984 12 27 2015 06 16 0140-6736 2 8411 1984 Nov 10 Lancet (London, England) Lancet Influence of propranolol on weight and salt and water homoeostasis in chronic liver disease. 1064-8 Sixteen patients with chronic liver disease were treated with propranolol or placebo in a double-blind study. Skinfold thickness, total body water and exchangeable sodium, and urinary sodium were measured (...) every 6 months for a year; body weight was measured every 2 (later every 3) months for 15 months. Propranolol treatment was associated with a significant rise in body weight after 9 months and significant rises in skinfold thickness and body fat after 12 months. Propranolol-treated patients showed a fall in total body water at 6 months and a rise in urinary sodium concentration at 12 months. They did not show the rise in total body exchangeable sodium that occurred in placebo-treated patients

Lancet1984

35. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis.

Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. 6361553 1984 02 14 1984 02 14 2013 11 21 0028-4793 309 25 1983 Dec 22 The New England journal of medicine N. Engl. J. Med. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. 1539-42 We conducted a prospective randomized trial of propranolol for the prevention of recurrent variceal bleeding in 48 patients with cirrhosis (...) of the liver. During a follow-up period of up to 21 months, 12 of 26 patients in the propranolol group and 11 of 22 in the control group had rebleeding from esophageal varices. There was no significant difference in rebleeding between the two groups. This contrasts with a previous report of the efficacy of propranolol in preventing recurrent gastrointestinal bleeding in alcoholic cirrhosis. The difference in results may be due to the inclusion in our study of patients with other causes of cirrhosis

NEJM1983

36. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results.

A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. 6358542 1984 01 07 1984 01 07 2016 10 17 0098-7484 250 20 1983 Nov 25 JAMA JAMA A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. 2814-9 The beta-Blocker Heart Attack Trial (BHAT) was a placebo-controlled, randomized, double-blind clinical trial of the long-term administration of propranolol hydrochloride to persons who had had at least one (...) confirmed myocardial infarction. Among 3,837 patients followed up for an average of 25 months, coronary incidence, defined as recurrent nonfatal definite reinfarction plus fatal coronary heart disease, in the propranolol group was 10.0%, compared with 13.0% in the placebo group, a reduction of 23%. The incidence of definite nonfatal reinfarction was lower by 15.6%, and that of definite or probable nonfatal reinfarction by 14.7%. Among patients with a history of congestive heart failure (CHF), 14.8% of

JAMA1983

37. Anti-platelet activity of beta-adrenergic antagonists: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment.

Anti-platelet activity of beta-adrenergic antagonists: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. 6118758 1982 02 22 1982 02 22 2015 06 16 0140-6736 2 8260-61 1981 Dec 19-26 Lancet (London, England) Lancet Anti-platelet activity of beta-adrenergic antagonists: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. 1382-4 Treatment of hypertensive patients with dl (...) -propranolol (640 mg/day) significantly inhibited thromboxane synthesis by their platelets and platelet aggregation induced by thrombin or arachidonic acid. The effects were dose-related and were also caused by the stereoisomer, d-propranolol (640 mg/day), which has very little beta-blocking activity. These findings suggest that the cardioprotective effects of propranolol may be due partly to this anti-platelet activity, to a reduction in thromboxane-induced coronary-artery vasoconstriction, or to both. d

Lancet1982

38. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.

A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. 7038157 1982 05 27 1982 05 27 2016 10 17 0098-7484 247 12 1982 Mar 26 JAMA JAMA A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. 1707-14 The beta-Blocker Heart Attack Trial (BHAT) was a National Heart, Lung, and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular (...) administration of propranolol hydrochloride to men and women who had experienced at least one myocardial infarction would result in a significant reduction in total mortality during a two- to four-year period. During a 27-month interval, 3,837 persons between the ages of 30 and 69 years were randomized to either propranolol (1,916 persons) or placebo (1,912 persons), five to 21 days after the infarction. Depending on serum drug levels, the prescribed maintenance dose of propranolol hydrochloride was either

JAMA1982

39. Comparison of propranolol and hydrochlorothiazide for thr initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. Veterans Administration Cooperative Study Group on Antihypertensive agents.

Comparison of propranolol and hydrochlorothiazide for thr initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences in response. Veterans Administration Cooperative Study Group on Antihypertensive agents. 6750166 1982 12 03 1982 12 03 2016 10 17 0098-7484 248 16 1982 Oct 22 JAMA JAMA Comparison of propranolol and hydrochlorothiazide for thr initial treatment of hypertension. I. Results of short-term titration with emphasis on racial differences (...) in response. Veterans Administration Cooperative Study Group on Antihypertensive agents. 1996-2003 We compared hydrochlorothiazide and propranolol hydrochloride for monotherapy of hypertension by a double-blind study of 683 men who were titrated to less than 90 mm Hg diastolic BP or to 640 mg of propranolol or 200 mg of hydrochlorothiazide. Propranolol reduced systolic BP from 146.0 +/- 14.4 (SD) to 134.8 +/- 16.3 mm Hg and diastolic BP from 101.6 +/- 4.6 to 90.5 +/- 7.5 mm Hg. Hydrochlorothiazide lowered

JAMA1982

40. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents.

Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents. 6750167 1982 12 03 1982 12 03 2016 10 17 0098-7484 248 16 1982 Oct 22 JAMA JAMA Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents. 2004-11 (...) As described in the preceding communication, either propranolol hydrochloride or hydrochlorothiazide were randomly allocated in a double-blind manner to 683 patients with initial diastolic BP in the range of 95 to 114 mm Hg. Of this number, 394 entered the long-term treatment phase. During the subsequent 12 months of long-term treatment, hydrochlorothiazide was more effective than propranolol in controlling BP (mean reductions, -17.5/-13.1 mm Hg with hydrochlorothiazide compared with -8.3/-11.3

JAMA1982